These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 30106639

  • 1. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
    Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK.
    J Clin Oncol; 2018 Oct 01; 36(28):2887-2894. PubMed ID: 30106639
    [Abstract] [Full Text] [Related]

  • 2. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
    Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabières C.
    BMC Cancer; 2024 Jun 10; 24(1):709. PubMed ID: 38853244
    [Abstract] [Full Text] [Related]

  • 3. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T.
    PLoS Med; 2020 Dec 10; 17(12):e1003489. PubMed ID: 33301466
    [Abstract] [Full Text] [Related]

  • 4. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S, Li Y, Liao Z, Wang Z, Wang Z, Li Y, Qian L, Zhao J, Zong H, Kang B, Zou WB, Chen K, He X, Meng Z, Chen Z, Huang S, Wang P.
    Gut; 2020 Mar 10; 69(3):540-550. PubMed ID: 31562239
    [Abstract] [Full Text] [Related]

  • 5. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, Jia X, Dong Z, Chen L, Wang Y, Tian Y.
    Int J Cancer; 2014 Jun 01; 134(11):2646-55. PubMed ID: 24615168
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM.
    Gut; 2018 Jan 01; 67(1):128-137. PubMed ID: 28108468
    [Abstract] [Full Text] [Related]

  • 8. N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer.
    Wen YR, Lin XW, Zhou YW, Xu L, Zhang JL, Chen CY, He J.
    World J Gastrointest Oncol; 2024 Mar 15; 16(3):659-669. PubMed ID: 38577461
    [Abstract] [Full Text] [Related]

  • 9. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K, Takano S, Iida F, Satoh M, Tsuchida S, Kawashima Y, Yoshitomi H, Sanda A, Kodera Y, Takizawa H, Mikata R, Ohtsuka M, Shimizu H, Miyazaki M, Yokosuka O, Nomura F.
    Br J Cancer; 2016 Oct 11; 115(8):949-956. PubMed ID: 27657339
    [Abstract] [Full Text] [Related]

  • 10. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
    Byeon S, McKay MJ, Molloy MP, Gill AJ, Samra JS, Mittal A, Sahni S.
    Int J Cancer; 2024 Jul 15; 155(2):365-371. PubMed ID: 38519999
    [Abstract] [Full Text] [Related]

  • 11. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J, Ploner A, Kordes M, Löhr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W.
    Int J Cancer; 2021 Apr 15; 148(8):2048-2058. PubMed ID: 33411965
    [Abstract] [Full Text] [Related]

  • 12. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR, Postier RG, Li M, Lerner MR, Lightfoot SA, Peyton MD, Deb SJ, Baker CM, Williams TL, Hanas RJ, Stowell DE, Lander TJ, Brackett DJ, Hanas JS.
    Cancer Lett; 2015 Apr 10; 359(2):314-24. PubMed ID: 25637792
    [Abstract] [Full Text] [Related]

  • 13. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A.
    Ann Surg; 2022 Jan 01; 275(1):e229-e237. PubMed ID: 32398486
    [Abstract] [Full Text] [Related]

  • 14. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung KH, Lee JC, Lee J, Cho IK, Kim J, Jang W, Yoo BC, Hwang JH.
    Pancreatology; 2020 Oct 01; 20(7):1465-1471. PubMed ID: 32873483
    [Abstract] [Full Text] [Related]

  • 15. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.
    J Natl Cancer Inst; 2017 Apr 01; 109(4):. PubMed ID: 28376157
    [Abstract] [Full Text] [Related]

  • 16. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S.
    Cancer Prev Res (Phila); 2021 Jul 01; 14(7):729-740. PubMed ID: 33893071
    [Abstract] [Full Text] [Related]

  • 17. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
    Sahni S, Pandya AR, Hadden WJ, Nahm CB, Maloney S, Cook V, Toft JA, Wilkinson-White L, Gill AJ, Samra JS, Dona A, Mittal A.
    Int J Cancer; 2021 Mar 15; 148(6):1508-1518. PubMed ID: 33128797
    [Abstract] [Full Text] [Related]

  • 18. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
    Lindgaard SC, Sztupinszki Z, Maag E, Chen IM, Johansen AZ, Jensen BV, Bojesen SE, Nielsen DL, Hansen CP, Hasselby JP, Nielsen KR, Szallasi Z, Johansen JS.
    Clin Cancer Res; 2021 May 01; 27(9):2592-2603. PubMed ID: 33737308
    [Abstract] [Full Text] [Related]

  • 19. Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection.
    Ney A, Nené NR, Sedlak E, Acedo P, Blyuss O, Whitwell HJ, Costello E, Gentry-Maharaj A, Williams NR, Menon U, Fusai GK, Zaikin A, Pereira SP.
    PLoS Comput Biol; 2024 Aug 01; 20(8):e1012408. PubMed ID: 39208354
    [Abstract] [Full Text] [Related]

  • 20. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, Nishiwada S, Sharma G, Cridebring D, Zenhausern F, Kim S, Roe DJ, Darabi S, Han IW, Evans DB, Yamada S, Demeure MJ, Becerra C, Celinski SA, Borazanci E, Tsai S, Kodera Y, Park JO, Bolton JS, Wang X, Kim SC, Von Hoff D, Goel A.
    Gastroenterology; 2022 Nov 01; 163(5):1252-1266.e2. PubMed ID: 35850192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.